It remains a major challenge to develop a selective and effective fibrinolytic system for
thrombolysis with minimal undesirable side effects. Herein, we report a multifunctional …

Purpose To test the hypothesis that thrombus-specific tissue plasminogen activator (tPA)-
loaded nanocarriers enhance thrombolytic efficacy and attenuate hemorrhagic …

Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

Accelerating thrombolysis using plasminogen activators (PAs) encapsulated liposomes or
PEG microparticles by pressure-driven permeation have been demonstrated in vitro and in …

Several plasminogen activators (PAs) have been found effective in treating different
thromboembolic diseases. However, administration of conventional thrombolytic therapy is …

Intravenous injection of thrombolytic drugs is the most effective strategy for the treatment of
thrombotic diseases. However, the clinical application of most thrombolytic drugs is limited …

Intravascular administration of plasminogen activators is a clinically important thrombolytic
strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic …

Tissue plasminogen activator (tPA), a widely used thrombolytic agent, has an application
limit due to short half-life. To prolong the half-life of tPA, liposomes composed of egg …

Background Fibrin-rich clot formation in thrombo-occlusive pathologies is currently treated
by systemic administration of plasminogen activators (eg tPA), to convert fibrin-associated …

Accelerated thrombolysis by pressure‐driven permeation has been demonstrated in in vitro
and in vivo animal models by using plasminogen activators (PAs) encapsulated liposomes …